Research and development of therapeutics should occur at the interface of academic research and medicine. At the Icahn School of Medicine at Mount Sinai, top scientists are making observations of great medical importance. Currently, these findings are freely published; however, conversion of the findings into products with clinical significance for new therapies or treatments often occurs elsewhere.
At the Center for Therapeutic Antibody Development (CTAD), we are committed to assisting investigators in the development of therapeutics based upon their own individual research findings. Calls for targets that have potentially unmet medical needs will be announced regularly, and assistance will be provided for antibody production, testing, and commercialization by CTAD and Mount Sinai Innovation Partners.